← Leaderboards
Adam Mark Staffaroni
University Of California, San Francisco
$4,706,290
Attributed
$4,706,290
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.5M · FY2019–25$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,706,290 · 4
By mechanism
RF1$2,371,437 · 1
K23$945,864 · 1
R01$798,073 · 1
U19$590,916 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Robert Scott Mackin$13,397,417
- Jeremy David Keenan$19,787,326
- Alexandra Dupont Crosswell$652,120
- Monica Gandhi$27,077,063
- Elaine Khoong$1,911,487
Others in their field
Other Emerging Leaders on “Clinical Trials”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$245,363,765
- Beth Baseler · Leidos Biomedical Research, Inc.$207,964,226
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$177,411,785
Research focus
Clinical TrialsEnrollmentDementiaNeurofilamentBiological MarkersOutcome MeasureResearch PersonnelTrainingNeuropsychologyClinical PredictorsNeurodegenerative DisordersSymptomsClinical Dementia Rating ScaleLightFamilyNerve DegenerationAgingFrontotemporal DementiaAffectFutureMutationPredictive ModelingMemoryMethodology
Grant awards (8)
Validating remote digital assessments for familial frontotemporal dementia$798,073
R01 · FY2025 · AG · contact PI
Technology and Remote Assessment Core$590,916
U19 · FY2025 · AG · contact PI
Optimizing Clinical Trial Endpoints in Frontotemporal Dementia$174,285
K23 · FY2023 · AG · contact PI
Validating remote digital assessments for familial frontotemporal dementia$2,371,437
RF1 · FY2022 · AG · contact PI
Optimizing Clinical Trial Endpoints in Frontotemporal Dementia$174,285
K23 · FY2022 · AG · contact PI
Optimizing Clinical Trial Endpoints in Frontotemporal Dementia$199,098
K23 · FY2021 · AG · contact PI
Optimizing Clinical Trial Endpoints in Frontotemporal Dementia$199,098
K23 · FY2020 · AG · contact PI
Optimizing Clinical Trial Endpoints in Frontotemporal Dementia$199,098
K23 · FY2019 · AG · contact PI